Present data and treatment schedule of aripiprazole in the treatment of schizophrenia;Données actuelles et modalités d'utilisation de l'aripiprazole dans le traitement de la schizophrénie

Encephale

Volumn 34, Issue 1, 2008, Pages 82-92

  Limosin, F ^a   Azorin, J M ^b   Krebs, M O ^c   Millet, B ^d   Glikman, J ^e   Camus, V ^f   Crocq, M A ^g   Costentin, J ^h   Dalery J ⁱ  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c CENTRE HOSPITALIER SAINTE ANNE   (France)

^d Service Hospitalo universitaire de Psychiatrie   (France)

^e EPS Ville Evrard   (France)

^f CHU BRETONNEAU   (France)

^g Centre Hospitalier de Rouffach   (France)

^h HÔPITAL CHARLES NICOLLE   (France)

ⁱ CENTRE HOSPITALIER LE VINATIER   (France)

Author keywords

Anti psychotic; Aripiprazole; Schizophrenia; Tolerance

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CYAMEMAZINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EFAVIRENZ; FLUOXETINE; HALOPERIDOL; ITRACONAZOLE; KETOCONAZOLE; LEVOMEPROMAZINE; NEVIRAPINE; OLANZAPINE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; PROTEINASE INHIBITOR; QUETIAPINE; QUINIDINE; RIFABUTIN; RIFAMPICIN; RISPERIDONE;

ANXIETY; ARTICLE; CLINICAL TRIAL; COGNITION; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; EXTRAPYRAMIDAL SYNDROME; FOLLOW UP; HUMAN; HYPERPROLACTINEMIA; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE SYNDROME; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUINOLONES; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 42749083725     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2007.12.003     Document Type: Article

References (36)

1. Abu-Tair, et al. Clozapine augmented with aripiprazole in 5 patients with schizophrenia. J Clin Psychopharmacol 26 6 (2006) 669-671
2. Barzman D.H., DelBello M.P., Kowatch R.A., et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolesc Psychopharmacol 14 4 (2004) 593-600
3. Beresford T.P., Clapp L., Martin B., et al. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 25 4 (2005) 363-366
4. Biederman J., McDonnell M.A., Wozniak J., et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr 10 2 (2005) 141-148
5. Brown E.S., Jeffress J., Liggin J.D., et al. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 66 6 (2005) 756-760
6. Chavez B., and Poveda R.A. Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances. Ann Pharmacother 40 12 (2006) 2265-2268
7. Chrzanowski W.K., Marcus R.N., Torbeyns A., et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52 - week, open-label comparison with olanzapine. Psychopharmacology 189 (2006) 259-266
8. Clarke D., et al. Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia. Aust NZJ Psychiatry 39 9 (2005) 840-841
9. Coffey G.L., Botts S.R., and de Leon J. High vulnerability to acute dystonic reactions: a case of antipsychotic exposure and uncontrolled seizure activity. Prog Neuropsychopharmacol Biol Psychiatry 29 5 (2005) 770-774
10. Crossman A.M., and Lindenmayer J.P. Tolerability of high-dose aripiprazole in treatment-refractory schizophrenic patients. J Clin Psychiatry 67 7 (2006) 1158-1159
11. Cutler A.J., Marcus R.N., Hardy S.A., et al. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacrebation of schizophrenia. CNS Spectr 11 9 (2006) 691-702
12. Feltenstein M.W., Altar C.A., and See R.E. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry 61 5 (2007) 582-590
13. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. US Depet Health, Educationand Welfare publication (ADM) 76-338 (1976), Md: National Institute of Mental Health, Rockville pp.218-22
14. Henderson D.C., Kunkel L., Nguyen D.D., et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 113 (2006) 142-147
15. Ingman K., Kupila J., Hyytia P., et al. Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol Alcohol 41 4 (2006) 391-398
16. Kane J.M., Carson W.H., Saha A.R., et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63 (2002) 763-771
17. Kane J.M., Meltzer H.Y., Carson Jr. W.H., et al., Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 68 2 (2007) 213-223
18. Kasper S., Zerman M.N., McQuade R.D., et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6 (2003) 325-337
19. Kay S.R., Fiszbien A., and Opler L.A. The Positive Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
20. Keck Jr. P.E., Marcus R., Tourkodimitris S., et al., Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160 9 (2003) 1651-1658
21. Kern R.S., GreenMF, and Cornblatt B.A. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology 187 (2006) 312-320
22. Kerwin R, Millet B, Herman E, Banki CM, Lublin M. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripiprazole (STAR) Study. Eur Psychiatry 2007;22:433-43.
23. Lieberman J.A. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18 4 (2004) 251-267
24. Lim S., Pralea C., Schnitt J., et al. Possible increased efficacy of low-dose clozapine when combined with aripiprazole. J Clin Psychiatry (2004) 1284-1285 65.9
25. Marder S.R., McQuade R.D., Stock E., et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61 2-3 (2003) 123-136
26. McQuade R.D., Stock E., Marcus R., et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65 suppl 18 (2004) 47-56
27. McEvoy J.P., Daniel D.G., CarsonJr W.H., et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 41 (2007) 895-905
28. Mitsonis CI, Dimopoulos NP, Mitropoulos PA et al. Aripiprazole augmentation in the management of residual symptoms in clozapine- treated outpatients with chronic schizophrenia: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006 Nov 6.
29. Pigott T.A., Carson W.H., Saha A.R., et al., Ingenito GG for the Aripriprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controled 26 - week study. J Clin Psychiatry 64 (2003) 1048-1056
30. Potkin S.G., Saha A.R., Kujawa M.J., et al. An antipsychotic with a novel mechanism of action, and risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 60 (2003) 681-690
31. Rocha F.L., and Hara C. Benefits of combining aripiprazole to clozapine: three case reports. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 1167-1169
32. Tandon R., Devellis R.F., Han J., et al., IAQ Validation Study Group. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res 136 2-3 (2005) 21121
33. Vito J., Jummani R., and Coffey B. Advanced pediatric psychopharmacology. J Child Adolesc Psychopharmacol 16 4 (2006) 498-502
34. Volavka J., Czobor P., Citrome L., et al. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. J Clin Psychiatry 66 11 (2005) 1362-1366
35. Ziegenbein, et al. Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia. Aust NZJ Psychiatry 39 9 (2005) 840-841
36. Ziegenbein, et al. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clin Drug Invest 26 3 (2006) 117-124